Tarsus Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M |
| Operating income | -$71.0M | -$120.6M | -$143.2M | -$62.7M | -$12.2M |
| Operating expenses | — | — | $160.6M | $88.5M | $69.2M |
| Cash from operations | -$12.5M | -$83.0M | -$117.5M | -$49.0M | $3.7M |
| Capital expenditure | $9.9M | $1.6M | $1.5M | $506,000 | $586,000 |
| Free cash flow | -$22.3M | -$84.6M | -$119.0M | -$49.5M | $3.2M |
| Total assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M |
| Total liabilities | $218.7M | $152.5M | $68.5M | $35.0M | $12.2M |
| Total debt | $75.0M | $75.0M | $30.0M | $20.0M | — |
Shares outstanding 43.0M · Free float 85.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.